CD8A and cancer: A novel theoretical foundation for cancer management against GC is the restoration of intestinal microbial butyrate, which increases CD8+ T-cell cytotoxicity through hydroxycarboxylic acid receptor 2 (HCA2), also known as GPR109A/HOP homeobox (HOPX) and inhibits GC carcinogenesis [64].